Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,184.87 -2.83 (-0.05%) Dow
39,033.05 +148.79 (+0.38%) Nasdaq
16,286.09 -46.46 (-0.28%) Bitcoin USD
62,313.89 -903.51 (-1.43%) CMC Crypto 200
1,327.08 +32.41 (+2.50%)
Aadi Bioscience, Inc. (AADI)
| Previous close | 2.1100 |
| Open | 2.1100 |
| Bid | 1.8200 x 100 |
| Ask | 1.8900 x 100 |
| Day's range | 1.7000 - 2.1100 |
| 52-week range | 1.5500 - 8.6000 |
| Volume | |
| Avg. volume | 344,578 |
| Market cap | 45.794M |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
- PR Newswire
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024 at 8:30 am EDT (5:30 am PDT) to report first quarter 2024 financial results and provide recent corporate updates.
- PR Newswire
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance. These data will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in
